Depression: How should psoriasis patients with a history of depression and/or suicidal ideation be managed?

This chapter is based on the previous chapter. A systematic search was conducted, details of which can be found in the Methods & Evidence report.

Results/Recommendations:
Psoriasis is associated with a higher risk for psychiatric comorbidities including anxiety and depression while results on suicide ideation and suicide are more unclear. In general, interventions that are effective for psoriasis correspondingly also improve symptoms of depression. Clinical studies using adalimumab, etanercept, ustekinumab, ixekizumab, guselkumab or fumarates for the treatment of psoriasis have shown that all these anti-inflammatory drugs not only improve psoriatic manifestations, but also symptoms of depression. In a head-to-head study, guselkumab was associated with greater improvements in symptoms of depression compared with adalimumab. In a prospective, longitudinal registry study, biologic therapy was found to have the greatest improvement on symptoms of depression followed by conventional systemic therapy and phototherapy. Taken together, these data suggest that the more effective the intervention for psoriasis, the greater the benefit to the mood. However, whether the overall beneficial effect on depressive symptoms is direct, or indirect (through improvement in psoriasis and therefore mood) is not clear.

Systemic treatments for psoriasis with special attention to a possible increased risk of depression, suicide ideation and completed suicide are discussed below:

Acitretin: Acitretin has been reported to be associated with depression in some case reports. However, more recent reviews of the literature conclude that except for very few cases of depression and suicidal ideation there are no convincing evidence-based data to support an association between acitretin and depression/suicidality. A formal review of retinoids (including acitretin and isotretionin) carried out by EMA's Pharmacovigilance Risk Assessment Committee in 2018 concluded that it was not possible to identify a clear increase in the risk of neuropsychiatric disorders in people taking oral retinoids compared to those that did not. However, the EMA decided to include a warning about the possible risk in the product information for oral retinoids, since PRAC noticed that severe skin disorders themselves increase the risk of psychiatric disorders. Based on the above, the guideline group did not consider there to be sufficient evidence to specifically counsel against use of acitretin in those patients with mood disorders but, in common with all systemic therapies, clinicians
should monitor for mood changes given that people with psoriasis are at increased risk of anxiety and depression.

**Brodalumab:** In two out of three phase III studies of efficacy and safety of brodalumab in patients with plaque psoriasis (AMAGINE 1-3) cases of suicide were reported (two patients in each of studies 1 and 2) \(^{21,22}\). An expert opinion (2019) discussing these observed cases of suicide highlighted the following aspects \(^ {23}\): Further review of the suicides by the Columbia Classification Algorithm of Suicide Assessment Review Board confirmed only three of the cases as suicides. All of them had underlying psychiatric disorders or stressors and all three suicides occurred at one center. Both symptoms of depression and anxiety decreased during treatment with brodalumab \(^ {22}\).

In the European SmPC, the reported Suicidal ideation and behaviour, including completed suicide in patients treated with brodalumab was mentioned. However, it was also stated that a causal association between treatment with brodalumab and increased risk of suicidal ideation and behaviour has not been established. In the SmPC, it is recommended that risk and benefit of treatment with brodalumab should be carefully weighed for patients with a history of depression and/or suicidal ideation. Patients, caregivers, and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal ideation, anxiety, or other mood changes, and they should contact their healthcare provider if such events occur. If a patient suffers from new or worsening symptoms of depression and/or suicidal ideation or behavior is identified, it was recommended to discontinue treatment with brodalumab \(^ {24}\).

**Apremilast:** Results from two phase III studies including patients with moderate-to-severe psoriasis (ESTEEM 1 and ESTEEM 2) with open-label extension for up to four years, showed that patient reported depression occurred in 1.4% of patients treated with apremilast and in 0.5% of receiving placebo. The incidence of depression did not increase over time. There was one suicide attempt, and no completed suicides with apremilast \(^ {25}\). Similar results were achieved in an open-label extension study (for up to additional four years) of three phase III studies of patients with psoriatic arthritis (PsA); 1.2% in patients treated with apremilast and 0.8% in patients receiving placebo. There were two suicide attempts, and no completed suicides with apremilast \(^ {26}\). Postmarketing experience, including five cases of completed suicides, was reported and a new safety information was published for apremilast provided by Celgene in agreement with the European Medicines Agency and the Health Products Regulatory Authority in 2016 \(^ {27}\). In here it was stated that evidence from clinical trials and postmarketing experience suggested a causal association between suicidal ideation and behaviour with the use of apremilast. The SmPC and patient leaflet for apremilast was updated to add a warning about depression (common adverse
reaction (≥1/100 to <1/10) and suicidal behavior and ideation (uncommon adverse reaction (≥1/1,000 to <1/100)) \(^2\).

It was recommended that risks and benefits of starting or continuing treatment with apremilast should be carefully assessed in patients with previous or existing psychiatric symptoms or if concomitant treatment with other medicinal products likely to cause psychiatric events are in use or intended. Additionally, it was recommended to discontinue treatment with apremilast in patients suffering from new or worsening psychiatric symptoms, or if suicidal ideation or suicidal attempt is identified.

**We recommend** to be aware of signs and symptoms of anxiety and depression in patients with psoriasis and monitor for symptoms of depression and/or suicidal ideation or anxiety during systemic treatments for psoriasis especially in those with a history of any of the above.

**We suggest** using alternatives to brodalumab and apremilast in patients with a history of depression and/or suicidal ideation.

\(^1\) due to personal-financial conflict of interest 3 abstentions

### References


